LTBR identified as potential target for cancer immunotherapy and marker of poor prognosis

A new research paper was published in Aging (listed by MEDLINE/PubMed as “Aging (Albany NY)” and “Aging-US” by Web of Science) Volume 16, Issue 1, entitled, “Systematic analysis of the prognostic value and immunological function of LTBR in human cancer.”

EMA Grants PRIME Status to Pentixapharm’s Lead Candidate PentixaFor – Biotech Investments

Pentixapharm Holding AG / Key word(s): Study EMA Grants PRIME Status to Pentixapharm’s Lead Candidate PentixaFor 18-Oct-2024 / 15:49 CET/CEST Disclosure of an inside information

October 19, 2024

FDA ad comm favors Zevra’s Niemann-Pick drug

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning! Today, we discuss

August 5, 2024

aNUma: Pioneering Psychological Wellbeing Technology for Serious Disease Care and Beyond | Psychedelic Invest

“We live in a “fix-it” culture with an expectation there’s a solution to every problem. But death is not a problem to solve. As has

January 10, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.